| Budget Amount *help |
¥19,110,000 (Direct Cost: ¥14,700,000、Indirect Cost: ¥4,410,000)
Fiscal Year 2012: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2011: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2010: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2009: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2008: ¥5,720,000 (Direct Cost: ¥4,400,000、Indirect Cost: ¥1,320,000)
|
|---|
| Research Abstract |
Estrogen receptor and androgen receptor participate sexual function as well as bone maintenance and nervous system. Creation of tissue selective ligands, which separate these functions, requires drug design in consideration of conformational change of receptor-ligand complex. In this project, we focused designand synthesis of new estrogen receptor ligands and androgen receptor ligands utilizing a new hydrophobic structure for the design. We have developed lead compounds for anti-osteoporosis agent and anti-prostate cancer agent which anti-androgen withdrawal syndrome.
|
